A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris

Pemphigus Vulgaris Clinical Trial

Official title:

An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment With the BTK Inhibitor PRN1008 in Patients With Newly Diagnosed or Relapsing Pemphigus Vulgaris

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02704429
• Other study ID #: PRN1008-005
• Secondary ID: 2015-003564-37
• Status: Completed
• Phase: Phase 2
• Start date: January 22, 2016
• Est. completion date: January 10, 2020

Study information

• Verified date: December 2022
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Open-label cohort study in adult patients with newly diagnosed or relapsing pemphigus vulgaris, with intra-patient dose-adjustment based on clinical response and BTK occupancy, and with conventional immunosuppressive "rescue treatment", if indicated. The duration of therapy in Part A will be 12 weeks, followed by 12 weeks of follow up. The extension phase, Part B includes 24 weeks of therapy, followed by 4 weeks of follow-up.

Description:

Primary Objectives:

To evaluate the safety of PRN1008 in patients with pemphigus vulgaris (PV)

To evaluate the clinical activity of PRN1008 in patients with PV, per criteria in the European Academy of Dermatology and Venereology (EADV) 2014 Pemphigus S2 Guideline (Hertl et al. 2015)

Secondary Objectives

To evaluate the pharmacokinetics (PK) and the pharmacodynamics (PD) of multiple doses of PRN1008 in patients with PV

To evaluate the relationship of PK and PD to each other and to efficacy and safety in this patient population

Recruitment information / eligibility

• Status: Completed
• Enrollment: 42
• Est. completion date: January 10, 2020
• Est. primary completion date: December 18, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Male or female patients, aged 18 to 80 years old, with biopsy-proven, mild-moderate PV (PDAI 8 to 45) in Part A and mild to severe PV in Part B (PDAI 8 to 60) that are either:

• newly diagnosed patients (i.e. naïve to an effective induction treatment regimen) for whom an initial period of PRN1008 monotherapy is judged clinically acceptable, or

• relapsing patients, for whom an initial period of PRN1008 monotherapy, or combination therapy with any of low dose corticosteroid, ie.0.5 mg/kg of prednis(ol)one per day

Exclusion Criteria:

• Pregnant or lactating women

• A history of malignancy of any type, other than surgically excised non-melanoma skin cancers or in situ cervical cancer within 5 years before the day of dosing

• Use of immunologic response modifiers with the following periods prior to Day 1: 1 week: cyclophosphamide; 4 weeks: intravenous immunoglobulin, Kinaret (anakinra) and Enbrel (etanercept); 12 weeks: Remicade (infliximab), Humira (adalimumab), Simponi (golimumab), Orencia (abatacept), Actemra (tocilizumab), Cimzia (certolizumab), Cosentyx (secukinumab), plasmapheresis; 6 months: Rituxan/MabThera (rituximab), ofatumumab, any other anti-CD20 antibody, other long acting biologics

• More than 0.5 mg/kg of prednis(ol)one per day ("low dose corticosteroids") within the two weeks prior to Day 1

• Use of proton pump inhibitor drugs such as omeprazole and esomeprazole

• Has received any investigational drug (or is currently using an investigational device) within the 30 days before receiving the first dose of study medication, or at least 5 times the respective elimination half-life time (whichever is longer)

• History of drug abuse within the precious 12 months

• Alcoholism or excessive alcohol use, defined as regular consumption of more than approximately 3 standard drinks per day

• Refractory nausea and vomiting, malabsorption, external biliary shunt, significant bowel resection that would preclude adequate study drug absorption

• History of anorexia nervosa or periods of three months or more of low body weight in the past 5 years

• Donation of a unit or more of blood or blood products within 4 weeks prior to Day 1

• History of solid organ transplant

• History of epilepsy or other forms of seizures in the last 5 years

• Positive for screening for human immunodeficiency virus, hepatitis B (surface and core antibodies unrelated to vaccination), or hepatitis C (anti-HCV antibody confirmed with Hep C RNA)

• History of active or latent tuberculosis (TB) infection (must test negative using the QuantiFERON test to be eligible)

• History of serious infections requiring intravenous (by catheter that delivers antibiotics into your blood) treatment

• Live vaccine within 28 days prior to baseline or plan to receive one during the study

Related Conditions & MeSH terms

• Pemphigus
• Pemphigus Vulgaris

Intervention

Drug:
• PRN1008
Part A dosing was initiated administering 400 mg BID. Intrapatient dose adjustments (reductions and increases) were permitted based upon tolerability and clinical response with the maximum dose allowed up to 600 mg BID for 12 weeks. Part B initial dosing was 400 mg QD for 2 weeks with dose escalation to 400 mg BID at the discretion of the Investigator for the purposes of investigating dose response and identifying the minimal efficacious dose of rilzabrutinib for 24 weeks.

Locations

Country	Name	City	State
Australia	Sinclair Dermatology	East Melbourne	Victoria
Australia	Premier Specialists	Kogarah	New South Wales
Australia	Royal Melbourne, Dermatology Office	Melbourne	Victoria
Croatia	Clinical Hospital Osijek	Osijek
Croatia	Klinichki Bolnicki Centar Zagreb	Zagreb
France	Hôpital Avicenne	Bobigny	Siene-Saint Denis
France	Rouen University Hospital	Rouen
Greece	Hospital of Venereal and Skin Diseases A.Syggros	Athens
Greece	University General Hospital of Ioannina	Ioánnina	Ioannina
Greece	University Hospital of Larissa	Larissa	Thessaly
Greece	Papageorgiou General Hospital of Thessaloniki	Thessaloniki
Israel	Chaim Sheba Medical Center	Ramat-Gan
Israel	Tel Aviv Sourasky Medical Center	Tel Aviv

Sponsors (2)

Lead Sponsor	Collaborator
Principia Biopharma, a Sanofi Company	Principia Biopharma Australia Pty Ltd.

Countries where clinical trial is conducted

Australia,  Croatia,  France,  Greece,  Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Treatment-emergent Adverse Events	Treatment-emergent adverse events (TEAEs) including clinically significant changes in physical examination, laboratory tests, and vital signs. An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment phase that was defined as the time from the start of study drug up to study completion.	Part A: until 24 weeks and Part B: until 28 weeks
Primary	Percentage of Participants Who Are Able to Achieve Control of Disease Activity (CDA) Within 4 Weeks of Starting PRN1008 Treatment Without the Need for Doses of Prednisone or Prednisolone >0.5 mg/kg	CDA was defined as the time at which new lesions cease to form and established lesions begin to heal.	4 weeks
Secondary	Percentage of Participants Able to Achieve Control of Disease Activity (CDA) Without Corticosteroids Within 4 Weeks	CDA was defined as the time at which new lesions cease to form and established lesions begin to heal.	4 weeks
Secondary	Percentage of Participants Able to Achieve a Complete Response (CR) Without Corticosteroids	CR was defined as complete healing of all lesions and the absence of new lesions.	Part A: 12 weeks treatment and Part B: 24 weeks treatment
Secondary	Percentage of Participants Able to Achieve Complete Remission (CR) Without the Need for Doses of Prednisone or Prednisolone of Greater Than 0.5mg/kg	CR was defined as complete healing of all lesions and the absence of new lesions.	Part A: 12 weeks treatment and Part B: 24 weeks treatment
Secondary	Time to Control of Disease Activity (CDA)	CDA was defined as the time at which new lesions cease to form and established lesions begin to heal. Kaplan-Meier estimate median time is reported.	Part A: until 24 weeks and Part B: until 28 weeks
Secondary	Time to End of Consolidation Phase (ECP)	ECP was defined as the time at which no new lesions have developed for minimum of 2 weeks, and approximately 80% of existing lesions have healed. The median time to ECP was based on Kaplan-Meier estimate which considered censoring at end of follow-up for patients who didn't have an event. A +/-3 days window for visits at Week 3 and 5, and +/-7 days window for visits at Week 9, 13, 17, 21, 25.	Part A: until 24 weeks and Part B: until 28 weeks
Secondary	Time to Complete Remission (CR)	CR was defined as complete healing of all lesions and the absence of new lesions.	Part A: until 24 weeks and Part B: until 28 weeks
Secondary	Time to Relapse After PRN1008 Treatment Discontinuation	Relapse was defined as appearance of =3 new lesions/month that do not heal spontaneously within 1 week, or by extension of established lesions, in a patient who has achieved disease control. The median time to relapse was based on Kaplan-Meier estimate which considered censoring at end of follow-up for patients who didn't have an event. A +/-3 days window for visits at Week 3 and 5, and +/-7 days window for visits at Week 9, 13, 17, 21, 25.	Part A: until 24 weeks and Part B: until 28 weeks
Secondary	Cumulative Corticosteroid Usage	Cumulative corticosteroid usage	Part A: until 24 weeks and Part B: until 28 weeks
Secondary	Percentage Change From Baseline in Pemphigus Disease Area Index (PDAI) Total Activity Scores	The PDAI questionnaire has 2 components including activity and damage. The activity component consists of skin, scalp and mucosa parts, and the damage component consists of skin and scalp parts. The total activity score was used for the summary of PDAI scores. PDAI total activity score = Total skin activity + Total scalp activity + Total mucosa activity. PDAI Total Activity Score ranged from 0 to 250 points representing disease activity (higher scores mean a worse outcome). Negative change in total activity score from baseline indicates improvement in pemphigus activity.	Part A: until 24 weeks and Part B: until 28 weeks
Secondary	Change From Baseline in Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) Total Activity Score	ABSIS Total Activity Score ranged from 0 to 206 points representing disease activity (higher scores mean a worse outcome). Negative change in total activity score from baseline indicates improvement in pemphigus activity.	Part A: until 24 weeks and Part B: until 28 weeks
Secondary	Change From Baseline in Autoimmune Bullous Diseases Quality of Life (ABQOL)	ABQOL score ranged from 0 to 68 points representing disease activity (higher scores mean a worse outcome).	Part A: until 24 weeks and Part B: until 28 weeks
Secondary	Change From Baseline in Treatment of Autoimmune Bullous Diseases Quality of Life (TABQOL) Scores	TABQOL score ranged from 0 to 68 points representing disease activity (higher scores mean a worse outcome).	Part A: until 24 weeks and Part B: until 28 weeks
Secondary	Change From Baseline in Appetite (SNAQ Score)	Simplified Nutritional Appetite Questionnaire (SNAQ) score ranged from 0 to 20 points representing disease activity (higher scores mean a better outcome).	Part A: until 24 weeks and Part B: until 28 weeks